LifeVantage Announces Positive In Vitro Results for New GLP-1 System Showing Synergistic Gene Activation for Enhanced Weight Management* †
LifeVantage (Nasdaq: LFVN) has announced positive in vitro results for its new GLP-1 system, designed to enhance weight management. The study, conducted on specialized L-cells in the colon, examined key genes involved in GLP-1 production and regulation. The two-product system showed synergistic gene activation, significantly increasing GLP-1 production through direct L-cell activation and gut microbiome optimization.
The research revealed downregulation of DPP-4 gene expression, allowing for more GLP-1 availability in the body. LifeVantage plans to introduce this innovative system in October, targeting new consumers and expanding market opportunities for its Consultants. The company emphasizes that these products are designed to activate optimal health processes at the cellular level, leveraging their unique Activation approach.
LifeVantage (Nasdaq: LFVN) ha annunciato risultati in vitro positivi per il suo nuovo sistema GLP-1, progettato per migliorare la gestione del peso. Lo studio, condotto su cellule L specializzate nel colon, ha esaminato i geni chiave coinvolti nella produzione e regolazione del GLP-1. Il sistema a due prodotti ha mostrato attivazione genica sinergica, aumentando significativamente la produzione di GLP-1 attraverso l'attivazione diretta delle cellule L e l'ottimizzazione del microbioma intestinale.
La ricerca ha rivelato una downregulation dell'espressione genica di DPP-4, permettendo una maggiore disponibilità di GLP-1 nel corpo. LifeVantage prevede di introdurre questo sistema innovativo a ottobre, puntando a nuovi consumatori e ampliando le opportunità di mercato per i suoi Consulenti. L'azienda sottolinea che questi prodotti sono progettati per attivare i processi di salute ottimale a livello cellulare, sfruttando il loro approccio unico di Attivazione.
LifeVantage (Nasdaq: LFVN) ha anunciado resultados in vitro positivos para su nuevo sistema GLP-1, diseñado para mejorar la gestión del peso. El estudio, realizado en células L especializadas en el colon, examinó genes clave involucrados en la producción y regulación del GLP-1. El sistema de dos productos mostró activación génica sinérgica, aumentando significativamente la producción de GLP-1 a través de la activación directa de las células L y la optimización del microbioma intestinal.
La investigación reveló una downregulación de la expresión génica de DPP-4, lo que permite una mayor disponibilidad de GLP-1 en el cuerpo. LifeVantage planea introducir este sistema innovador en octubre, dirigido a nuevos consumidores y ampliando las oportunidades de mercado para sus Consultores. La empresa enfatiza que estos productos están diseñados para activar procesos de salud óptimos a nivel celular, aprovechando su enfoque único de Activación.
LifeVantage (Nasdaq: LFVN)는 체중 관리를 강화하기 위해 설계된 새로운 GLP-1 시스템의 긍정적인 인 비트로 결과를 발표했습니다. 이 연구는 대장에서 전문화된 L 세포를 대상으로 GLP-1 생산 및 조절과 관련된 주요 유전자를 조사했습니다. 두 제품 시스템은 유전자 활성화의 시너지 효과를 보여주었으며, L 세포의 직접적인 활성화와 장내 미생물군 최적화를 통해 GLP-1 생산을 상당히 증가시켰습니다.
연구 결과는 DPP-4 유전자 발현의 조절 감소를 나타내어 체내에서 GLP-1의 가용성을 높였습니다. LifeVantage는 10월에 이 혁신적인 시스템을 소개할 계획이며, 새로운 소비자를 겨냥하고 자문가를 위한 시장 기회를 확장합니다. 이 회사는 이러한 제품이 독특한 활성화 접근 방식을 활용하여 세포 수준에서 최적의 건강 프로세스를 활성화하도록 설계됐다고 강조합니다.
LifeVantage (Nasdaq: LFVN) a annoncé des résultats in vitro positifs pour son nouveau système GLP-1, conçu pour améliorer la gestion du poids. L'étude, réalisée sur des cellules L spécialisées dans le côlon, a examiné des gènes clés impliqués dans la production et la régulation du GLP-1. Le système composé de deux produits a montré une activation génétique synergique, augmentant de manière significative la production de GLP-1 grâce à une activation directe des cellules L et à l'optimisation du microbiome intestinal.
La recherche a révélé une régulation à la baisse de l'expression génique de DPP-4, permettant une plus grande disponibilité de GLP-1 dans le corps. LifeVantage prévoit de lancer ce système innovant en octobre, visant de nouveaux consommateurs et élargissant les opportunités de marché pour ses Consultants. L'entreprise souligne que ces produits sont conçus pour activer des processus de santé optimaux au niveau cellulaire, en tirant parti de leur approche unique d'activation.
LifeVantage (Nasdaq: LFVN) hat positive In-vitro-Ergebnisse für sein neues GLP-1-System angekündigt, das darauf abzielt, das Gewichtsmanagement zu verbessern. Die Studie, die an spezialisierten L-Zellen im Dickdarm durchgeführt wurde, untersuchte wichtige Gene, die an der Produktion und Regulation von GLP-1 beteiligt sind. Das Zwei-Produkt-System zeigte synergistische Genaktivierung und erhöhte signifikant die GLP-1-Produktion durch die direkte Aktivierung der L-Zellen und die Optimierung des Mikrobioms im Darm.
Die Forschung zeigte eine Herabregulierung der DPP-4-Genexpression, die für eine höhere Verfügbarkeit von GLP-1 im Körper sorgt. LifeVantage plant, dieses innovative System im Oktober einzuführen, um neue Verbraucher anzusprechen und die Marktchancen für seine Berater zu erweitern. Das Unternehmen betont, dass diese Produkte darauf ausgelegt sind, optimale Gesundheitsprozesse auf zellulärer Ebene zu aktivieren, und dabei ihren einzigartigen Aktivierungsansatz nutzen.
- In vitro study showed significant increase in GLP-1 production
- Synergistic activation of key genes responsible for GLP-1 synthesis and regulation
- Downregulation of DPP-4 gene expression, potentially increasing GLP-1 availability
- New product system to be introduced in October, expanding market opportunities
- Potential to attract new consumers and tap into an untapped market
- Results are based on in vitro studies only, not yet proven in human trials
- Efficacy and safety in actual weight management not yet demonstrated
- Potential regulatory challenges as product claims are not evaluated by FDA
The in vitro study results for LifeVantage's new GLP-1 system are intriguing, but it's important to approach them with caution. While the data shows promising gene activation and increased GLP-1 production, these are preliminary findings from a controlled laboratory environment. The synergistic effects on key genes (GCG, PCSK1, GLP1R) and the downregulation of DPP-4 are particularly noteworthy, as they suggest a potential for enhanced GLP-1 activity. However, it's important to note that in vitro results don't always translate directly to human outcomes. The dual-mechanism approach targeting both L-cells and the gut microbiome is innovative, but clinical trials will be necessary to confirm efficacy and safety in humans. Investors should be aware that the path from promising lab results to a marketable weight management product can be long and uncertain.
LifeVantage's announcement could potentially impact its market position in the competitive health and wellness sector. The GLP-1 market is experiencing rapid growth, driven by the success of prescription medications. If LifeVantage can successfully bring this product to market, it could tap into a lucrative segment. However, investors should consider that the product launch is planned for October and its success will depend on regulatory approval, marketing effectiveness and consumer acceptance. The company's stock (LFVN) may see increased volatility as the market reacts to this news. It's worth noting that LifeVantage's direct selling model could provide a unique distribution advantage, potentially leading to faster market penetration if the product proves effective. Financial performance will ultimately depend on the product's efficacy and the company's ability to scale production and sales.
LifeVantage's entry into the GLP-1 market with a naturally-derived, non-prescription product could be a game-changer. The weight management market is booming, with consumers increasingly seeking alternatives to prescription medications. This product's dual-action approach might appeal to health-conscious consumers looking for a more holistic solution. However, the company will face stiff competition from established brands and prescription GLP-1 agonists with proven clinical efficacy. The success of this product will largely depend on its ability to deliver noticeable results and LifeVantage's marketing strategy. The October launch timing is strategic, potentially capitalizing on New Year's resolutions. Investors should monitor initial sales data and consumer feedback closely, as these will be critical indicators of the product's market potential and long-term impact on LifeVantage's revenue streams.
Recent findings reveal how LifeVantage’s two-product system activates GLP-1 production through targeted gene expression and microbiome support*
SALT LAKE CITY, Sept. 10, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is pleased to announce the promising results of an in vitro study that investigated the combined effects of its upcoming two-product system on activating GLP-1 production.*
The study, which began in May and concluded at the end of June 2024, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.
Key genes involved in the production and regulation of GLP-1 were thoroughly examined, including:
- GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis.
- PCSK1: Encodes for enzymes that cleave Proglucagon into active GLP-1.
- GLP1R: Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity.
- DPP-4: An enzyme that degrades GLP-1, reducing the amount available in the body.
The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body’s GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of eight naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches and fibers.*
Results from the in vitro study revealed not only a significant increase in GLP-1 production but also a synergistic activation of the key genes responsible for its synthesis and regulation. Notably, there was a downregulation of DPP-4 gene expression, which allows for more GLP-1 to be available to work within the body.*
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
†Results may vary. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.
“This in vitro study confirms the harmonious nature of our innovative two-product system that approaches GLP-1 activation through both direct activation of L-cells and optimizing the gut microbiome in the colon to enhance GLP-1 production,” said Lisa Barnes, Vice President of Research and Development at LifeVantage. “With the development of this system, LifeVantage continues to leverage our unique Activation approach, using the latest science and naturally-derived ingredients to help your body make what it needs to be healthy.”*
“LifeVantage remains committed to ensuring our Consultants experience business success with products that are second to none,” said Steve Fife, President and CEO. “This product will open doors to new consumers and an untapped market, adding to our already industry-leading Consultant opportunity. We are excited by the scientific evidence supporting the claims of our new GLP-1 system and we are thrilled to be able to introduce the this system beginning in October.”*
For further information about LifeVantage and Activation, please visit LifeVantage.com.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the activation company, is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and probiotics, weight management, and skin and hair care products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, the TrueScience® line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs and Axio®, its nootropic energy drink mixes. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*
Public Relations Contact:
Jennifer Rumble, CerconeBrownCompany
(704) 923-6378
jrumble@cerconebrown.com
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
†Results may vary. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.
FAQ
What are the key findings of LifeVantage's GLP-1 system study?
When will LifeVantage (LFVN) launch its new GLP-1 system?
How does LifeVantage's GLP-1 system work?
What genes were examined in LifeVantage's GLP-1 system study?
